Cancer gene therapy: Scientific basis

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 437-452

  Wadhwa, Punit D ^a   Zielske, Steven P ^a   Roth, Justin C ^a   Ballas, Christopher B ^a   Bowman, Janice E ^a   Gerson, Stanton L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Angiogenesis; Chemotherapy resistance genes; Dendritic cells; Suicide genes; Tumor suppressor genes

Indexed keywords

ACICLOVIR; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CD40 LIGAND; CISPLATIN; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DIHYDROFOLATE REDUCTASE; ENDOSTATIN; FLUCYTOSINE; FLUOROURACIL; GAMMA INTERFERON; GANCICLOVIR; GAP JUNCTION PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; ONYX 015; PROTEIN P53; THYMIDINE KINASE; TRIMETREXATE; TUMOR ANTIGEN; TUMOR EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BONE MARROW; BYSTANDER EFFECT; CANCER; CANCER IMMUNOLOGY; CANCER RESISTANCE; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUICIDE GENE; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANIMALS; CLINICAL TRIALS; GENE THERAPY; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 0036181023     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104039     Document Type: Review

References (86)

1. WAF1, a potential mediator of p53 tumor suppression
2. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
3. Up-regulation of Fas (CD95) in human p53 wild-type cancer cells treated with ionizing radiation
4. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
5. p53 tumor suppressor gene therapy for cancer
6. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
7. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect
8. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
9. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
10. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
11. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors
12. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro
13. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus
14. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication
15. Prodrug-activating systems in suicide gene therapy
16. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus
17. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo
18. Gene therapy of metastatic colon carcinoma: Regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase
19. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy
20. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant
21. Tumor angiogenesis: Therapeutic implications
22. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
23. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
24. Pericytes in the microvasculature
25. Blood vessel maturation: Vascular development comes of age
26. Antiangiogenic gene therapy
27. Gene therapy strategies for tumor antiangiogenesis
28. Antiangiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo
29. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo
30. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
31. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model
32. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice
33. Angiogenesis in cancer and other diseases
34. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
35. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells
36. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
37. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells
38. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity
39. + T cell help to elicit protective and therapeutic antitumor immunity
40. Murine tyrosinase expressed by a T7 vector in bone marrow-derived dendritic progenitors effectively prevents and eradicates melanoma tumors in mice
41. Tumor regression induced by intra-tumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells
42. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors
43. Human T lymphocyte genetic modification with naked DNA
44. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity
45. Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors
46. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model
47. The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer
48. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma
49. Biochemistry of multidrug resistance mediated by the multidrug transporter
50. Transfer and expression of the human multiple drug resistance gene into live mice
51. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1
52. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit
53. Preselection of transduced murine hematopoietic stem cell populations leads to increased long-term stability and expression of the human multiple drug resistance gene
54. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
55. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow
56. A gene transfer strategy for making bone marrow cells resistant to trimetrexate
57. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity
58. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction
59. Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells
60. Active site-directed double mutants of dihydrofolate reductase
61. In vivo selection of retrovirally transduced hematopoietic stem cells
62. Characterization of a novel reaction by human O6-alkylguanine-DNA alkyltransferase with 1,3-bis(2-chloroethyl)-1-nitrosourea-treated DNA
63. Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine
64. Mutations in human O6-alkylguanine-DNA alkyltransferase imparting resistance to O6-benzylguanine
65. Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells
66. Engineering human DNA alkyltransferases for gene therapy using random sequence mutagenesis
67. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine
68. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells
69. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector
70. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate non-myeloablated mice after drug selection
71. Creation of a fully functional human chimeric DNA repair protein. Combining O6-methylguanine DNA methyltransferase (MGMT) and AP endonuclease (APE/redox effector factor 1 (Ref 1)) DNA repair proteins
72. Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside
73. A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs
74. Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate
75. Efficient protection of cells from the genotoxicity of nitrosoureas by the retrovirus-mediated transfer of human O6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1
76. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene
77. Gene therapy for chronic myelogenous leukemia (CML): A retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo
78. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
79. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
80. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
81. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
82. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
83. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
84. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
85. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor
86. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients